Share Name Share Symbol Market Type Share ISIN Share Description
Mercia Asset Management Plc LSE:MERC London Ordinary Share GB00BSL71W47 ORD 0.001P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.10 -0.47% 21.40 169,243 08:02:48
Bid Price Offer Price High Price Low Price Open Price
21.00 21.80 21.50 21.40 21.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 10.68 2.57 0.86 24.9 94
Last Trade Time Trade Type Trade Size Trade Price Currency
12:54:35 O 10,000 21.36 GBX

Mercia Asset Management (MERC) Latest News

More Mercia Asset Management News
Mercia Asset Management Investors    Mercia Asset Management Takeover Rumours

Mercia Asset Management (MERC) Discussions and Chat

Mercia Asset Management Forums and Chat

Date Time Title Posts
25/11/202016:00Mercia Technologies PLC868
01/8/201907:15Mercia Technologies PLC59
29/1/201421:58The new SL500 came today14
24/11/201107:05Merchant Secs37

Add a New Thread

Mercia Asset Management (MERC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-11-26 12:54:3621.3610,0002,136.00O
2020-11-26 12:33:1421.357516.01O
2020-11-26 12:33:1021.7625,0005,440.00O
2020-11-26 10:44:4021.7025,0005,425.00O
2020-11-26 10:29:4921.80100,00021,800.00O
View all Mercia Asset Management trades in real-time

Mercia Asset Management (MERC) Top Chat Posts

Mercia Asset Management Daily Update: Mercia Asset Management Plc is listed in the General Financial sector of the London Stock Exchange with ticker MERC. The last closing price for Mercia Asset Management was 21.50p.
Mercia Asset Management Plc has a 4 week average price of 18.75p and a 12 week average price of 17.75p.
The 1 year high share price is 33.50p while the 1 year low share price is currently 13.50p.
There are currently 440,109,707 shares in issue and the average daily traded volume is 391,479 shares. The market capitalisation of Mercia Asset Management Plc is £94,183,477.30.
varies: redartbmud In answer to your posting on 10 November I do perceive an advantage for MERC shareholders in successes achieved by the Managed Funds. The better they perform, the more subscriptions they attract and the greater the fees that MERC can charge. Far and away my best investment success in recent years has been in IPX. The share price has risen nearly 12 fold in about 4 years and much of this is attributable to the success of the funds they manage. Their only quoted investment trust is, I believe, Impax Environmental. This has outperformed most in its sector but IPX shares have done much, much better. IPX specialises in investments acceptable to institutions worried about Climate Change and this is a large factor in its success. If MERC makes good money for those invested n its managed funds, then MERC's shareholders will benefit too.
sev22: It was only just over a month ago that 5 Directors bought shares in the company for 20p, including one Non-Exec spending nearly £250,000. I think these are well worth picking up below that price. 25 September 2020 Mercia Asset Management PLC ("Mercia" or the "Company") Director/PDMR Dealings Mercia Asset Management PLC (AIM: MERC), the proactive, regionally focused specialist asset manager with c.GBP800 million of assets under management, announces that it has received a notification of the following transactions relating to Ordinary shares of GBP0.00001 each in the capital of Mercia ("Ordinary Shares") by Directors and PDMRs of the Company as follows: -- Ian Metcalfe, Non-Executive Chair of the Company, became beneficially interested in a further 50,000 Ordinary Shares. The Shares were bought yesterday at 20.00p per share. -- Ray Chamberlain, Non-Executive Director of the company, became beneficially interested in a further 1,200,000 Ordinary Shares. The Shares were bought by the Forward Innovation Fund yesterday at 20.00p per share. -- Martin Glanfield, Director and Chief Financial Officer of the Company, became beneficially interested in a further 171,495 Ordinary Shares. The Shares were bought on his behalf yesterday at 20.00p per share by his SIPP. -- Julian Viggars, Director and Chief Investment Officer of the Company, became beneficially interested in a further 52,910 Ordinary Shares. The Shares were bought on his behalf yesterday at 18.90p per share by his SIPP. -- Peter Dines, PDMR and Chief Operating Officer of the Company, became beneficially interested in a further 50,000 Ordinary Shares. The Shares were bought yesterday at 20.00p per share.
pavey ark: Oxygen looks very good but ndreams could be even bigger.....either would double the share price if they were sold or this would point up the potential in the rest of the portfolio. The management here have come in for criticism but they have done/are doing everything they said they would do........including investing in the company. As usual private investors have taken the share price as a reflection of management's effort/abilities and that is seldom the case.
redartbmud: Merc 'The gift that keeps giving' - to the directors. Mercia Asset Management PLC (AIM: MERC), the proactive, regionally focused specialist asset manager, announces that options (the "Options") over a total of 9,497,000 new Ordinary shares with a nominal value of £0.00001 each in the capital of the Company ("Ordinary Shares") were granted after the market closed on 21 August 2020, pursuant to the 2014 Mercia Company Share Option Plan, at an exercise price of 21.50p per Ordinary Share (being the closing mid-market price of an Ordinary Share on 21 August 2020). The Options will, subject to the satisfaction of the performance condition, vest in three equal tranches on the third, fourth and fifth anniversary of the date of grant of the Options.
sev22: Thank you for the link. Edison have produced an excellent detailed research report on Mercia here which all investors would be well advised to read. Mercia’s shares continue to trade at a severe discount to current NAV of 32.1p per share. Add the additional 4.5p per share set out below gives a potential total value of at least 36.6p versus a latest closing price of 18.5p (shares are trading at half price). Valuation: 0.60x NAV + £20m for MFM Mercia’s shares continue to trade at a discount to NAV (0.60x), even before considering the embedded value of Mercia Fund Managers (MFM), which we estimate could be worth an additional 4.5p per share or more on top of NAV. Catalysts for a re-rating include further scaling of the business, commercialisation of the direct investment portfolio and/or successful exits.
redartbmud: Mercia Asset Management PLC ("Mercia" the "Company" or the "Group") Sale of The Native Antigen Company Mercia Asset Management PLC (AIM:MERC), the proactive, regionally focused specialist asset manager, is pleased to announce the profitable sale of The Native Antigen Company Limited ("NAC") to LGC, a global leader in the life sciences tools sector, for a total cash consideration of up to £18.0million. Mercia held a 29.4% fully diluted direct holding in NAC at the date of sale and will receive initial cash proceeds of £4.8million, with up to a further £0.4million receivable upon finalisation of customary closing working capital calculations. Based upon the total anticipated amount receivable of £5.2million, the total realised return above the £2.7million holding value as at 30 September 2019, will be a further £2.5million. Of this, £0.6million will be included as a fair value increase in the Group's results for the year end ended 31 March 2020, which will be announced on 14 July 2020. The remaining balance of £1.9million will be recognised as a realised gain in the Group's interim results for the six months to 30 September 2020. The sale is anticipated to generate an 8.4x return on its original direct investment cost and a 65% internal rate of return ("IRR"). Mercia first invested in NAC in 2011 through its third-party managed funds (which as at 31 March 2020 held an additional combined 20.9% stake) and subsequently, from its own balance sheet as a direct investment in December 2014. In addition to the direct investment returns, the sale will generate a 12.1x return on a blended third-party managed funds investment cost and a 31% funds IRR. Mercia has proactively supported NAC since its first day of trading, including representation from Mercia's Chief Operating Officer Peter Dines, as a non-executive director on the NAC board through to exit. Founded in 2010, as a divestiture from a University of Birmingham spinout company, NAC has become one of the world's leading suppliers of infectious disease reagents and is widely acknowledged to be a primary source of reagents for the study of emerging diseases. Dr Mark Payton, Mercia Asset Management, CEO, said: "Keeping to our commitment of realising balance sheet investments within a three to seven year period from initial investment, NAC is the fourth full cash exit from our direct investment portfolio. It has been an excellent investment for Mercia and this sale is a strong demonstration of the value which our differentiated model can create; for investors in our managed funds, shareholders in Mercia and the founders we back. NAC is an example of an innovative regional business sourced through Mercia's network, supported initially by our managed fund capital and then scaled using our own balance sheet capital. "Mercia plays a critical role in helping the UK's most exciting regional businesses scale and I am proud of the part we have played in NAC's journey, not just as the major capital provider but also as a critical partner in helping the business achieve its potential. I look forward to watching as they continue to go from strength to strength with their new owner." Yet another transformational sale by Merc - Not. Underwhelmed from Uttoxeter.
gwr7: I bought some today. I used a fill or kill order. I'm with wan on this one. Omega Diagnostics is part of the government supported consortium that is developing Point of Care antibody tests to help show the extent of immunity to SARS-CoV-2 in the population. These tests could offer some redemption for a government that took the wrong approach early on and has been scrambling to catch up ever since. The University of Oxford has identified the best allergen to use in the POC test. The partners, including Omega Diagnostics and BBI solutions, will develop and distribute the tests, assuming they are sufficiently accurate. Oxford have been leading on testing the failed antibody kits. There has been a lot of press about the Chinese tests. The government seems to have been held to ransom over these. They agreed to pay up front between £3m and £17m for millions of tests (depending on what you read) that simply don't work. They are no doubt making a claim through paypal. Best of British with that, but it shows how desperate they are for the tests. If they get approval for the POC test, the market could be millions for the UK and possibly billions worldwide as many countries need tests in order to determine who has antibodies, and a bit further down the line, immunity to the SARS-CoV-2 virus. I believe we'll get the working POC test. I've been invested in Omega for four years and I know they have the best experience in the game having developed the world's only semi-quantitive POC test for antibodies on a specific type of T cell in HIV patients. The test estimates a concentration of those T cells in the blood. The covid test is easier in the sense that the first iteration gives a simple yes/no answer to presence of antibodies but the difficulty is achieving the accuracy to keep false positives and negatives to an absolute minimum which is essential for the intended use. The test has to be at least 98% accurate, the higher the better so the top companies in their fields are working on it. I mentioned BBI solutions earlier and they have partnered with the Native Antigen Company based in Oxford. They will be producing antigens for the tests. You can see that if the POC test gets approval that is a big deal for NAC. On a separate though related issue, here is an interesting link hTTps:// Omega also has a distribution network in China. Maybe we can show China how to do it! Ideally I would hold shares in NAC but direct ownership is not possible for me. The good news is I know a company that does. Mercia Asset Management have 32.7% Obviously it would be daft to buy in just because of this but they have other promising companies within and without the covid space. I like the way they pick them. Most of the admin costs are covered by the profitable asset management business and they are a lead investment manager for the government’s northern powerhouse initiative. I believe the drive to support quality businesses oop north has legs. Add to that the share price was beaten down by forced sales from Woodford and Invesco funds, and is at a big discount to NAV limiting downside. It looks like a good investment to me. It is definitely long term so it is not going to multi-bag in weeks like other shooting stars of the minute but I believe it will do in time. One of the reasons Woodford failed was that Hargreaves Lansdown were using their promotional fund rankings to funnell investors into his funds who weren’t suited to them. Woodford was the goose that laid the golden egg but that was with high quality income companies. HL turned a blind eye to the investments making up his funds after he set up on his own, and also their open-ended nature. When PIs wanted to withdraw money en masse there wasn’t the liquidity in the smaller companies Woodford had invested in. Redemptions couldn’t be covered without disastrous forced sales. I think Mercia was a good pick by him. Obviously the Mercia share price performance has been poor since launch and that has upset investors. Also they shunned PIs in a discounted placing last year at 25p which forced an apology in the FT so hopefully they learnt from that. Mercia’s investments in companies take time to realise their true value and they need some high profile company sales or IPOs to cement their reputation. I think they’ll achieve them. As ever DYOR.
chimers: The big news accompanying half-time results from recently rebranded Mercia Asset Management plc (see New brand, new focus, new chair for Mercia) is an agreement to acquire the venture capital trust (VCT) fund management business of NVM Private Equity LLP for up to £25m cash and shares. The acquisition will be part-funded by a £30m placing at 25p per share, a not insubstantial 22% discount to Mercia’s 32p closing price yesterday. This is a significant acquisition for Mercia, boosting its VCT portfolio by some £270m, and increasing Mercia’s total assets under management by over 50% to £770m. Both Mercia and NVM are prolific investors in UK tech, sometimes in the same business (see Mercia and mates pop more dosh into Voxpopme). On the face of it, this deal makes good sense. Mercia gets a huge boost to its core VCT business, while (I assume) NVM gets to focus on its knitting (small management buyouts). I met up again with Mercia CEO Mark Payton just the other week. He has taken Mercia from being a Midlands-focused university spin-out investor to a publicly quoted, regionally focused broad-based backer of young, high-growth UK tech companies. Payton reiterated his aim to grow Mercia into an operationally profitable business (not there yet) with £1b of assets under management. The NVM deal gets him substantially closed to the latter objective. Prudent management will be required to achieve the former. Update: Just heard back from Mark Payton - the NVM deal will push Mercia into monthly profitability and he expects they will be profitable on a trading basis in FY2021. Good stuff!
bb123: Mercia Fund Management - (MERC) presentation Manchester Tuesday 17 Dec Shares and AJ Bell Investor Evening in Manchester View online version Register for the Shares investor evening Shares would like all delegates to enjoy their Christmas with our compliments. A bottle of champagne awaits you to take away at the end of the evening! The following companies will be presenting Amryt Pharma, Mercia Fund Management and Surface Transforms. Register now Tuesday 17 December 2019 Macdonald Manchester Hotel, London Road, Manchester, M1 2PG Registration: 18:00 | Presentations: 18:30 Sponsored by AJ Bell Youinvest Companies presenting Amryt Pharma - (AMYT) Amryt Pharma - (AMYT) a revenue-generating orphan drug company focused on acquiring, developing and commercialising products that help improve the lives of patients. Mercia Fund Management - (MERC) Mercia Fund Management - (MERC) is now known as Mercia Fund Managers or Mercia is part of Mercia Technologies PLC. It is a UK-based venture capital fund manager. The company provides venture capital to businesses focused on innovative technologies. Surface Transforms – (SCE) Surface Transforms – (SCE) Develops and manufactures carbon ceramic products mainly for the brakes market. The firm engages in developing new products and application of carbon fiber reinforced ceramic materials. Register now During the event and afterwards over drinks, investors will have the chance to: Discover new investment opportunities Discover new investment opportunities Get to know the companies better Get to know the companies better Talk with the company directors Talk with the company directors This email has been sent to you by AJ Bell Media Limited as you have requested to receive information from Shares magazine, Stock Market Wire, other AJ Bell Media websites or have registered for one of our events. If you would like to stop receiving emails, you can
wan: Brad_K...Mercia has 303m shares in issue (not sure where the other 2-3m came from) - Mercia Technologies PLC Placing of new Ordinary Shares to raise c.£40.0m 31/01/2017 hTTps:// 16 February 2017 Mercia Technologies PLC Result of General Meeting & Completion of Placing Following Admission, the Company will have 300,602,232 Ordinary shares in issue. hTTps:// I seem to recall the CEO saying that going forward Mercia's model would be sustainable i.e. future funding requirements would be provided by a combination of revenues from funds under management and importantly exits.
Mercia Asset Management share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Mercia Ass..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201127 06:42:39